Supplementary Data File S7 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models

Supplementary Data File S7 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models

<p>Related to Figure 2 - RD</p>

-д хадгалсан:

Номзүйн дэлгэрэнгүй
Үндсэн зохиолч:	Katie E. Hebron (15046889) (author)
Бусад зохиолчид:	Xiaolin Wan (15046892) (author), Jacob S. Roth (15046895) (author), David J. Liewehr (15046898) (author), Nancy E. Sealover (15046901) (author), William J.E. Frye (15046904) (author), Angela Kim (15046907) (author), Stacey Stauffer (15046910) (author), Olivia L. Perkins (15046913) (author), Wenyue Sun (15046916) (author), Kristine A. Isanogle (15046919) (author), Christina M. Robinson (15046922) (author), Amy James (15046925) (author), Parirokh Awasthi (15046928) (author), Priya Shankarappa (15046931) (author), Xiaoling Luo (15046934) (author), Haiyan Lei (14963261) (author), Donna Butcher (15046937) (author), Roberta Smith (15046940) (author), Elijah F. Edmondson (14950075) (author), Jin-Qiu Chen (15046943) (author), Noemi Kedei (15046946) (author), Cody J. Peer (14946853) (author), Jack F. Shern (14938001) (author), W. Douglas Figg (15046949) (author), Lu Chen (15046952) (author), Matthew D. Hall (14938004) (author), Simone Difilippantonio (15046955) (author), Frederic G. Barr (15046958) (author), Robert L. Kortum (15046961) (author), Robert W. Robey (15046964) (author), Angelina V. Vaseva (14949310) (author), Javed Khan (15046967) (author), Marielle E. Yohe (15046970) (author)
Хэвлэсэн:	2025
Нөхцлүүд:	Cancer Therapeutic Research and Development Methods and Technology Drug Targets Cell surface receptor drug targets Protein kinase & phosphatase drug targets Pediatric Cancers Preclinical Models Animal models of cancer Translational Research
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!

Ижил төстэй зүйлс

Supplemental Data File S3 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
-н: Katie E. Hebron (15046889)
Хэвлэсэн: (2025)

Supplementary Data File S1 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
-н: Katie E. Hebron (15046889)
Хэвлэсэн: (2025)

Supplementary Data File S2 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
-н: Katie E. Hebron (15046889)
Хэвлэсэн: (2025)

Supplementary Data File S6 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
-н: Katie E. Hebron (15046889)
Хэвлэсэн: (2025)

Supplementary Data File S8 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
-н: Katie E. Hebron (15046889)
Хэвлэсэн: (2025)

Supplementary Data File S9 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
-н: Katie E. Hebron (15046889)
Хэвлэсэн: (2025)

Supplementary Dataset S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
-н: Srivandana Akshintala (16610490)
Хэвлэсэн: (2025)

Supplementary Table S5 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
-н: Srivandana Akshintala (16610490)
Хэвлэсэн: (2025)

Supplementary Table S1 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
-н: Clare F. Malone (14960925)
Хэвлэсэн: (2025)

Supplementary Table S2 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
-н: Clare F. Malone (14960925)
Хэвлэсэн: (2025)

Supplementary Table S3 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
-н: Clare F. Malone (14960925)
Хэвлэсэн: (2025)

Supplementary Figure 1 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
-н: Anne-Florence Blandin (15056366)
Хэвлэсэн: (2025)

Supplementary Figure 2 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
-н: Anne-Florence Blandin (15056366)
Хэвлэсэн: (2025)

Supplementary Figure 3 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
-н: Anne-Florence Blandin (15056366)
Хэвлэсэн: (2025)

Supplementary Figure 4 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
-н: Anne-Florence Blandin (15056366)
Хэвлэсэн: (2025)

Supplementary Figure 5 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
-н: Anne-Florence Blandin (15056366)
Хэвлэсэн: (2025)

Supplementary Figure 6 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
-н: Anne-Florence Blandin (15056366)
Хэвлэсэн: (2025)

Supplementary Tables 1-8 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
-н: Anne-Florence Blandin (15056366)
Хэвлэсэн: (2025)

Supplementary Video 1 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis
-н: Debarati Mukherjee (15134436)
Хэвлэсэн: (2025)

Supplementary Video 2 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis
-н: Debarati Mukherjee (15134436)
Хэвлэсэн: (2025)

Supplementary Video 3 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis
-н: Debarati Mukherjee (15134436)
Хэвлэсэн: (2025)

Supplementary Video 4 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis
-н: Debarati Mukherjee (15134436)
Хэвлэсэн: (2025)

Figure S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
-н: Evan C. Chen (15054014)
Хэвлэсэн: (2025)

Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
-н: Evan C. Chen (15054014)
Хэвлэсэн: (2025)

Figure S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
-н: Evan C. Chen (15054014)
Хэвлэсэн: (2025)

Figure S4 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
-н: Evan C. Chen (15054014)
Хэвлэсэн: (2025)

Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
-н: Evan C. Chen (15054014)
Хэвлэсэн: (2025)

Figure S6 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
-н: Evan C. Chen (15054014)
Хэвлэсэн: (2025)

Supplementary Table 2 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
-н: Yuncheng Bei (16546095)
Хэвлэсэн: (2025)

Supplementary Table S1 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
-н: Yuncheng Bei (16546095)
Хэвлэсэн: (2025)

Supplementary Table S3 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
-н: Yuncheng Bei (16546095)
Хэвлэсэн: (2025)

Figure S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
-н: Yuanqing Ma (15052437)
Хэвлэсэн: (2025)

Figure S2 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
-н: Yuanqing Ma (15052437)
Хэвлэсэн: (2025)

Figure S3 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
-н: Yuanqing Ma (15052437)
Хэвлэсэн: (2025)

Figure S4 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
-н: Yuanqing Ma (15052437)
Хэвлэсэн: (2025)

Figure S5 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
-н: Yuanqing Ma (15052437)
Хэвлэсэн: (2025)

Figure S6 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
-н: Yuanqing Ma (15052437)
Хэвлэсэн: (2025)

Figure S7 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
-н: Yuanqing Ma (15052437)
Хэвлэсэн: (2025)

Figure S8 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
-н: Yuanqing Ma (15052437)
Хэвлэсэн: (2025)

Supplemental Figure S1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
-н: Zev A. Wainberg (15047031)
Хэвлэсэн: (2025)

Cannot write session to /tmp/vufind_sessions/sess_an5pio6916h0qsi0jv5j3762c3